Top Banner
Australian & New Zealand Journal of Psychiatry 47(12) 1136–1151 DOI: 10.1177/0004867413499077 © The Royal Australian and New Zealand College of Psychiatrists 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav anp.sagepub.com Australian & New Zealand Journal of Psychiatry, 47(12) Introduction The greatest mistake in the treatment of diseases is that there are physicians for the body and physicians for the soul, although the two cannot be separated (Plato) Our understanding of the role of the immune system and autoimmunity in psychiatry is evolving. A large body of evidence points to a role for inflammatory mediators and immune dysregulation in the pathogenesis of psychiat- ric disorders such as schizophrenia, depression, and Alzheimer’s disease (Fan et al., 2007; Krishnadas and Cavanagh, 2012; Moscavitch et al., 2009; Zotova et al., 2010). More recently, evidence has accumulated suggest- ing that inflammation and immune dysregulation play an important role in neuroprogression in bipolar disorders (Berk et al., 2011). Immune dysregulation and autoimmunity in bipolar disorder: Synthesis of the evidence and its clinical application Sanil Rege 1,2,3 and Suzanne J Hodgkinson 4,5 Abstract Objective: Increasing evidence suggests that inflammation and immune dysregulation play an important role in the pathogenesis of bipolar disorder. Because the brain can be affected by various autoimmune processes, it is possible that some psychiatric disorders may have an autoimmune basis. Method: This article reviews the literature on peripheral and central immune dysregulation and autoimmunity in bipo- lar disorder. The mechanisms of the innate and adaptive immune systems in the pathophysiology of bipolar disorder are explored. The clinical features and pathogenesis of neuropsychiatric systemic lupus erythematosus, anti-NMDA encephalitis, and Hashimoto’s encephalopathy are summarized. Results: Neuroinflammation and peripheral immune dysregulation may play a role in the pathophysiology of bipolar dis- order. This involves a complex interaction between immune cells of the central nervous system and periphery resulting in cellular damage through mechanisms involving excitotoxicity, oxidative stress, and mitochondrial dysfunction. Neu- ropsychiatric systemic lupus erythematosus, anti-NMDA encephalitis, and Hashimoto’s encephalopathy are important differentials for a psychiatrist to consider when suspecting autoimmune encephalopathy. Conclusions: The link between immune dysregulation, autoimmunity, and bipolar disorder may be closer than pre- viously thought. Psychiatrists should be vigilant for autoimmunity in presentations of bipolar disorder due to its high morbidity and therapeutic implications. Advances in neuroimaging and biomarker identification related to immune dys- regulation and neuroinflammation will contribute to our knowledge of the pathophysiology of bipolar disorder. Keywords Anti-NMDA encephalitis, autoimmunity, bipolar disorder, cytokines, Hashimoto’s encephalopathy, immune dysregulation, microglia, neuroinflammation, neuropsychiatric systemic lupus erythematosus, oligodendrocytes 1 Peninsula Health Mental Health Service, Frankston, Australia 2 Positive Psychology Wellness Centre, Mornington, Australia 3 Psych Scene, Australia 4 University of New South Wales (UNSW), Sydney, Australia 5 Liverpool Hospital, Liverpool, Australia Corresponding author: Sanil Rege, 1 Ross Street, Mornington, VIC 3931, Australia. Email: [email protected] 499077ANP 47 12 10.1177/0004867413499077ANZJP ArticlesRege and Hodgkinson 2013 Review
16

Immune dysregulation and autoimmunity in bipolar disorder ......clinical application Sanil Rege1,2,3 and Suzanne J Hodgkinson4,5 Abstract Objective: Increasing evidence suggests that

Sep 07, 2020

Download

Documents

dariahiddleston
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Immune dysregulation and autoimmunity in bipolar disorder ......clinical application Sanil Rege1,2,3 and Suzanne J Hodgkinson4,5 Abstract Objective: Increasing evidence suggests that

Australian & New Zealand Journal of Psychiatry47(12) 1136 –1151DOI: 10.1177/0004867413499077

© The Royal Australian and New Zealand College of Psychiatrists 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.navanp.sagepub.com

Australian & New Zealand Journal of Psychiatry, 47(12)

IntroductionThe greatest mistake in the treatment of diseases is that there are physicians for the body and physicians for the soul, although the two cannot be separated (Plato)

Our understanding of the role of the immune system and autoimmunity in psychiatry is evolving. A large body of evidence points to a role for inflammatory mediators and immune dysregulation in the pathogenesis of psychiat-ric disorders such as schizophrenia, depression, and Alzheimer’s disease (Fan et al., 2007; Krishnadas and Cavanagh, 2012; Moscavitch et al., 2009; Zotova et al.,

2010). More recently, evidence has accumulated suggest-ing that inflammation and immune dysregulation play an important role in neuroprogression in bipolar disorders (Berk et al., 2011).

Immune dysregulation and autoimmunity in bipolar disorder: Synthesis of the evidence and its clinical application

Sanil Rege1,2,3 and Suzanne J Hodgkinson4,5

Abstract

Objective: Increasing evidence suggests that inflammation and immune dysregulation play an important role in the pathogenesis of bipolar disorder. Because the brain can be affected by various autoimmune processes, it is possible that some psychiatric disorders may have an autoimmune basis.

Method: This article reviews the literature on peripheral and central immune dysregulation and autoimmunity in bipo-lar disorder. The mechanisms of the innate and adaptive immune systems in the pathophysiology of bipolar disorder are explored. The clinical features and pathogenesis of neuropsychiatric systemic lupus erythematosus, anti-NMDA encephalitis, and Hashimoto’s encephalopathy are summarized.

Results: Neuroinflammation and peripheral immune dysregulation may play a role in the pathophysiology of bipolar dis-order. This involves a complex interaction between immune cells of the central nervous system and periphery resulting in cellular damage through mechanisms involving excitotoxicity, oxidative stress, and mitochondrial dysfunction. Neu-ropsychiatric systemic lupus erythematosus, anti-NMDA encephalitis, and Hashimoto’s encephalopathy are important differentials for a psychiatrist to consider when suspecting autoimmune encephalopathy.

Conclusions: The link between immune dysregulation, autoimmunity, and bipolar disorder may be closer than pre-viously thought. Psychiatrists should be vigilant for autoimmunity in presentations of bipolar disorder due to its high morbidity and therapeutic implications. Advances in neuroimaging and biomarker identification related to immune dys-regulation and neuroinflammation will contribute to our knowledge of the pathophysiology of bipolar disorder.

KeywordsAnti-NMDA encephalitis, autoimmunity, bipolar disorder, cytokines, Hashimoto’s encephalopathy, immune dysregulation, microglia, neuroinflammation, neuropsychiatric systemic lupus erythematosus, oligodendrocytes

1Peninsula Health Mental Health Service, Frankston, Australia2Positive Psychology Wellness Centre, Mornington, Australia3Psych Scene, Australia4University of New South Wales (UNSW), Sydney, Australia5Liverpool Hospital, Liverpool, Australia

Corresponding author:Sanil Rege, 1 Ross Street, Mornington, VIC 3931, Australia. Email: [email protected]

499077 ANP471210.1177/0004867413499077ANZJP ArticlesRege and Hodgkinson2013

Review

Page 2: Immune dysregulation and autoimmunity in bipolar disorder ......clinical application Sanil Rege1,2,3 and Suzanne J Hodgkinson4,5 Abstract Objective: Increasing evidence suggests that

Rege and Hodgkinson 1137

Australian & New Zealand Journal of Psychiatry, 47(12)

The link between autoimmunity and psychiatric symp-toms has long been recognized, and W. Osler offered a description of psychosis in systemic lupus erythematosus (SLE) in 1895. In neurology, the identification of a range of autoantibodies acting on specific synaptic sites in the brain has been an important development as these disorders can present initially to psychiatrists. This requires psychiatrists to remain vigilant for the possibility of autoimmune disor-ders mimicking psychiatric syndromes (Davison, 2012; Rosenfeld and Dalmau, 2011). Because the brain can be affected by various autoimmune processes, it is possible that some psychiatric disorders may have an autoimmune basis. We review the literature on peripheral and central nervous system (CNS) immune dysregulation and autoim-munity in bipolar disorder. The mechanisms of the innate and adaptive immune systems in the pathophysiology of bipolar disorder are explored. The clinical features and pathogenesis of neuropsychiatric systemic lupus erythema-tosus, anti-NMDA encephalitis, and Hashimoto’s encepha-lopathy are summarized.

Evidence of immune dysregulation in bipolar disorder

The immune system can broadly be divided into the innate and adaptive immune systems, or cell-mediated immunity and humoral immunity. The innate immune system is the first and immediate line of defence against pathogens; it consists of monocytes, monocyte-derived dendritic cells and macrophages, neutrophils, natural killer cells, mast cells, and various cytokines and chemokines, such as inter-feron (IFN) γ, interleukin (IL) 1, IL-6, and tumour necrosis factor α (TNF-α) (Fearon and Locksley, 1996). By contrast, adaptive immunity occurs after a latent phase and is primar-ily activated by antigen-presenting cells, which include macrophages and dendritic cells (Nguyen et al., 2002). The adaptive immune response, once activated through antigen recognition receptors on the surface of T cells called pattern recognition receptors, is mediated by T (CD4 and CD8) and B lymphocytes. CD8 T cells are cytotoxic and are responsi-ble for destroying intracellular pathogens, whereas CD4 T cells or T-helper cells play critical roles in immunomodula-tion through the secretion of cytokines which are signalling molecules involved in the on-going activation and recruit-ment of immune cells (Zhu and Paul, 2008). The four key CD4 T cells are Th1, Th2, Th17, and Treg cells. Th1 cells release pro-inflammatory cytokines, such as IFN γ, TNF, and IL-2; Th2 cells release IL-4, IL-5, and IL-10, which act as regulators and anti-inflammatory cytokines and are responsible for activation of humoral immunity via the acti-vation of B cells through IL-4 (Bellone, 2005; Mosmann and Sad, 1996; Waite and Skokos, 2012). Th17 and Treg cells play important but different roles in the pathogenesis of autoimmunity (La Cava, 2009; Stockinger and Veldhoen, 2007). T cells and cytokines thus form an important

component of cell-mediated immunity. An optimal balance between anti-inflammatory and pro-inflammatory cytokines is vital for the optimal functioning of the immune response (Ng et al., 2003). B cells, however, play an important role in antibody-mediated or humoral immunity through the pro-duction of antibodies against foreign antigens.

The majority of the studies on bipolar disorder have focussed on cell-mediated immunity by measuring inflam-matory markers and cytokines, finding specific patterns of cytokine levels. A recent large meta-analysis showed ele-vated levels of TNF-α, soluble tumour necrosis factor receptor type 1 (sTNF-R1) and soluble interleukin-2 recep-tor (sIL-2R) in manic patients, compared to healthy control subjects and euthymic bipolar patients. The levels of sTNF-R1 were also elevated in bipolar euthymic patients com-pared to healthy control subjects (Munkholm et al., 2013). In addition to the presence of elevated acute-phase proteins, including haptoglobin and C-reactive protein, complement levels, such as C3C and C4 concentrations, have been found to be elevated in bipolar disorder (Maes et al., 1997; O’Brien et al., 2006; Wadee et al., 2002). There appears to be a phasic difference in the level of cytokines in manic bipolar patients, who show elevated plasma levels of TNF-α, IL-2, and IL-4 (Ortiz-Dominguez et al., 2007). Increases in the levels of IL-8 and IL-6 have been reported in depressed bipolar patients (Brietzke et al., 2009). There is evidence of stage-related abnormalities in cytokines; all interleukins and TNF-α are elevated in the early stages of illness, whereas in the later stages of illness, TNF-α and IL-6 continue to be elevated, but IL-10 does not. Thus, these cytokines may serve as important markers of disease progression in bipolar disorder (Kauer-Sant’Anna et al., 2009). Berk et al. (2011) have hypothesized that inflamma-tory mediators are involved in the episode-related cognitive decline seen in bipolar disorder. Bipolar patients in the euthymic state also have abnormalities in their chemokine levels that induce chemotaxis (i.e. the movement of leuko-cytes towards sites of inflammation), indicating ongoing inflammation in a clinically quiescent stage of illness (Brietzke et al., 2009). Leptin is an adipocyte-derived cytokine that is of interest in the pathogenesis of bipolar disorder as it plays an important role in obesity and pro-motes Th1 cell differentiation modulating immune responses (La Cava and Matarese, 2004). Insulin-like growth factor (IGF)-1 has been implicated in the pathogen-esis of bipolar disorder, insulin resistance, and immune dysfunction and may be a future biomarker of interest (Smith, 2010; Squassina et al., 2013).

Does neuroinflammation play a role in the pathophysiology of bipolar disorder?

Neuroinflammation is the result of an immune response in the CNS that involves a complex interaction between the

Page 3: Immune dysregulation and autoimmunity in bipolar disorder ......clinical application Sanil Rege1,2,3 and Suzanne J Hodgkinson4,5 Abstract Objective: Increasing evidence suggests that

1138 ANZJP Articles

Australian & New Zealand Journal of Psychiatry, 47(12)

CNS innate immune system, the blood–brain barrier (BBB) and the peripheral immune system. Microglia are the first line of defence in the CNS. Neuronal injury, infection, or ischaemia can activate microglia through specialized recep-tors on their surface called pattern recognition receptors. Three major families of pattern recognition receptors exist; Toll-like receptors (TLR), Nod-like receptors (NLR), and RIG1 like receptors, which recognize specific exogenous and endogenous ligands activating specific inflammatory pathways (Lampron et al., 2013). TLR and NLR can recog-nize pathogen-associated molecular patterns (PAMPs) dur-ing infection or damage-associated molecular patterns (DAMPs) such as intracellular protein and non-protein products and nucleic acids during neuronal injury. The engagement of microglial TLR activates transcription fac-tors such as NF-KB and mitogen-associated protein kinase leading to the release of inflammatory cytokines (e.g. IL-1β, TNF-α, IL-6), chemokines acting as chemoattract-ants for other immune cells, reactive oxygen species, nitric oxide, and prostanoids by activating the phospholipase A2 and COX-2 pathway. Although microglial activation is an important component of innate immunity serving to protect the CNS from harmful stimuli, under some poorly under-stood circumstances, microglia can become overactivated and cause neurotoxicity and neurodegeneration. Two pos-tulated signals are direct stimulation by endogenous pro-teins or environmental toxins and neuronal damage-released DAMPs recognizable by microglial TLR (Block et al., 2007; Ransohoff and Brown, 2012).

Activated microglia express indoleamine 2,3-dioxyge-nase, which diverts the tryptophan pathway towards pro-ducing tryptophan catabolites: of these, 3-HK generates free-radical species that can cause oxidative stress and lipid peroxidation, whereas quinolic acid is associated with glu-tamate-induced oxidative damage via NMDA receptor-mediated, calcium-dependent uncoupling of neuronal mitochondrial electron transport (Berk et al., 2011; Dugan et al., 1995; Najjar et al., 2013). The cytokine IL-1β increases NMDA receptor (NMDAR) contributing to gluta-mate-mediated neurotoxicity (Viviani et al., 2003). Kaindl et al. (2012) showed that activation of the NMDAR on microglia triggers inflammation and cell death, which in turn can further activate microglia and initiate a forward feedback loop (Kaindl et al., 2012). Glutamate can activate a Th1 response, and it plays an important role in immu-nomodulation, particularly the initiation and development of T cell-mediated immunity in the periphery and CNS (Pacheco et al., 2007). Cytokines can upregulate neuronal serotonin transporter activity reducing the strength of sero-tonin activity at serotonin receptors (Mössner et al., 1998; Zhu et al., 2005). Cytokines such as IL-6 and TNF-α acti-vate the hypothalamic–pituitary–adrenal axis, increasing cortisol levels which can be neurotoxic and may be central to the pathogenesis of depressive symptoms and cognitive deficits (Daban et al., 2005; Dunn, 2000). Elevated cortisol

levels reduce postsynaptic serotonin receptors, serotonin responsiveness, and brain-derived neurotrophic factor lev-els, thus affecting neurotransmitter regulation and neuro-plasticity (Huang and Reichardt, 2001; Issa et al., 2010; Miller et al., 1999). The strongest clinical evidence for the pathogenic role of cytokines comes from the effects of IFN-α in the treatment of hepatitis C and cancer (Renault et al., 1987). IFN-α administration is associated with widespread bilateral increases in glucose metabolism in subcortical regions including the basal ganglia (Capuron et al., 2007) and anterior cingulated, which are associated with fatigue and cognitive effects respectively (Capuron et al., 2005).

Microglia interact closely with other glial cells, namely astrocytes and oligodendrocytes, that play important roles in neural, cognitive, and behavioural functions (Najjar et al., 2013). Astrocytes maintain BBB integrity, regulate synaptic transmission, and are responsible for downregulat-ing harmful inflammation initiated by microglia by activat-ing the Th2 response and D2 receptors. Astrocytes express TLR and can amplify the CNS innate immune response by secreting complement components and chemokines. Astrocytes reduce the effects of excitotoxic glutamate by increasing their uptake, and inflammatory responses in the CNS can compromise this essential astrocyte function, thus amplifying excitotoxicity in the CNS (Zuo et al., 2010; Luo and Chen, 2012). Cross-talk between microglia and astro-cytes has been implicated in several neurological condi-tions, but the details of this interaction are still unclear (Liu et al., 2011b).

The third glial cell, the oligodendrocyte, is actively involved in the process of myelination and can downregu-late the inflammatory response of microglia by secreting anti-inflammatory cytokines (Edgar and Sibille, 2012; Najjar et al., 2013). TNF-α has a direct toxic effect on oli-godendroglia, potentially contributing to apoptosis and demyelination (Miller et al., 2009), and it is inversely related to the brain-derived neurotrophic factor concentra-tion, which is known to be reduced in bipolar disorder (Brietzke and Kapczinski, 2008; Kapczinski et al., 2009; Lin, 2009). Oligodendrocytes are particularly susceptible to oxidative stress and mitochondrial injury as they contain low levels of antioxidant glutathione and express NMDAR which exposes them to glutamate excitotoxicity (Bradl and Lassmann, 2010). The release of reactive oxygen species and nitric oxide not only amplifies the release of pro-inflammatory cytokines, but reactive oxygen species also leads to mitochondrial injury by activating oxidative and apoptotic pathways (Lopez-Armada et al., 2013) creating a vicious cycle of inflammation, oxidative and nitrosative stress (O&NS), and glutamate excitotoxicity. Furthermore, the activation of the O&NS pathways can damage mem-brane fatty acids and anchorage molecules such as palmitic acid and myristic acid, causing aberrations in cell signal transduction, cellular architecture, cell differentiation, and neuroprogression (Maes et al., 2012a).

Page 4: Immune dysregulation and autoimmunity in bipolar disorder ......clinical application Sanil Rege1,2,3 and Suzanne J Hodgkinson4,5 Abstract Objective: Increasing evidence suggests that

Rege and Hodgkinson 1139

Australian & New Zealand Journal of Psychiatry, 47(12)

The innate immune response can be further amplified by a breakdown in the BBB. Leukocytes in the peripheral cir-culation can bind to the endothelial cells of the BBB through adhesion molecules such as VCAM-1 and ICAM-1 and can pass through the BBB due to a loosening of the endothelial tight junctions (Rossi et al., 2011). Peripheral cytokines can enter the BBB through areas of the brain that lack the BBB, such as the circumventricular organs (Dantzer et al., 2000), and the vagus nerve acts as a connec-tion between the peripheral immune system and the brain (Gidron et al., 2007). In the CNS, inflammation results in the production of inflammatory mediators such as TNF-α, IL-6, IL-1β, and arachidonic acid (AA), which can increase BBB permeability (Shalev et al., 2009). Locally produced cytokines can also either activate neurons that project to specific brain areas or diffuse into the brain parenchyma by volume transmission to reach their targets (Dantzer et al., 2000). In summary, microglial activation results in the acti-vation of an inflammatory cascade that produces a range of downstream mediators that can have the net effect of caus-ing oligodendrocyte apoptosis, BBB damage, mitochon-drial dysfunction, and neuronal injury.

Studies have shown evidence of neuroinflammation in individuals with bipolar disorder. Postmortem studies in bipolar disorder have shown the presence of excitotoxic markers and neuroinflammation in the frontal cortex with activation of the IL-1 receptor cascade (Rao et al., 2010). The cytokine IL-1β, which is indicative of microglial acti-vation, was found to be elevated in the CSF of euthymic patients who had a recent manic or hypomanic episode (Soderlund et al., 2011). The cingulate cortex shows evi-dence of upregulation of the initiating step of the kynure-nine pathway and increased cell adhesion molecule immunoreactivity, indicating neuroinflammation (Miller et al., 2006; Thomas et al., 2004). Zanetti et al. (2009), using diffusion-tensor imaging, found disruptions in the ventromedial prefronto-limbic-striatal white matter in bipolar depression, which were hypothesized to result from inflammatory causes (Zanetti et al., 2009). Bipolar-type presentations with mania and hypomania have been described with IFN-α (Chang et al., 2005; Constant et al., 2005; Iancu et al., 1997; Malek-Ahmadi, 2001). Elevated levels of glutamate, markers of oxidative stress, and mito-chondrial dysfunction are found in the brains of individuals with bipolar disorder (Andreazza et al., 2008; Clay et al., 2011; Gigante et al., 2012; Hashimoto et al., 2007).

Glial cell abnormalities have been found; however, the data are not consistent and are affected by confounders such as medication and phases of illness (Najjar et al., 2013). Astrocyte involvement is indicated by decreased glial fibrillary acidic protein mRNA in the cingulate cortex (Webster et al., 2005). Reduced oligodendrocyte density, decreased oligodendrocyte gene expression in the frontal cortex, and white matter involvement have also been detected. (Edgar and Sibille, 2012). White matter

hyperintensities, which can indicate abnormal myelination, are found early on in bipolar disorder and play an important role in the pathophysiology of bipolar disorder through a postulated role of disconnectivity between the frontal cor-tex and regions controlling emotional regulation (McIntosh et al., 2008; Mahon et al., 2010; Manji et al., 2000). Further evidence for glial cell loss comes from the levels of S100B, which is actively released by astro- and oligodendrocytes. Significant increases in serum S100B have been observed during episodes of mania and depression, although not in euthymic patients; S100B has therefore been proposed as a biomarker for mood disorders (Schroeter et al., 2013). Individuals with bipolar disorder show a marked increase in the upregulation of pro-apoptotic genes along with a downregulation of antioxidant genes, inducing vulnerabil-ity to apoptosis and oxidative stress-induced damage (Benes et al., 2006). The combination of neuronal damage through the above mechanisms and the suppression of neu-rogenesis (Das and Basu, 2007; Losif et al., 2006) creates an environment biased towards neuroprogression that may be implicated in the pathogenesis of symptoms of bipolar disorder. A detailed explanation of the interaction between cytokines, O&NS stress, mitochondrial dysfunction, apop-totic pathways, and neurogenesis is outside the scope of this review and we refer readers to the articles by Berk et al. (2011) and Maes et al. (2011) for further reading.

Interestingly, the above-described pathways, namely mitochondrial dysfunction, neuroinflammation, and oligo-dendrocyte abnormalities, show parallels with multiple sclerosis (Konradi et al., 2012), which makes it important to examine the role of autoreactive T and B cells in the pathophysiology of bipolar disorder (discussed in the next section). Because cytokines play a crucial role in the devel-opment, differentiation, and regulation of immune cells, the dysregulation of cytokine production is thought to have an important role in the development of autoimmune disease (O’Shea et al., 2002). TLR and NLR are an important link between innate and adaptive immunity and may be respon-sible for the initiation of the autoimmune response (dis-cussed later). Moreover O&NS and apoptotic pathways release immunogenic self-epitopes from damaged mem-branes and proteins that can result in secondary autoim-mune reactions (Maes et al., 2011).

Peripheral autoimmunity and bipolar disorder

Autoimmunity is defined as a process whereby an immu-nological response is directed against the body’s self-anti-gens. Autoimmune disease occurs when the immune reaction overwhelms the normal tolerance checkpoints and occurs even in the absence of an offending antigen (Fairweather, 2007; Goodnow, 2007). A common feature of autoimmune diseases is the presence of autoantibodies, which are important markers in the diagnosis and

Page 5: Immune dysregulation and autoimmunity in bipolar disorder ......clinical application Sanil Rege1,2,3 and Suzanne J Hodgkinson4,5 Abstract Objective: Increasing evidence suggests that

1140 ANZJP Articles

Australian & New Zealand Journal of Psychiatry, 47(12)

classification of autoimmune diseases and can be useful in psychiatric clinical practice to detect an autoimmune pro-cess. Autoimmune tissue damage can be cell-mediated via T cell activity (cell-mediated immunity), antibody-mediated via B cells (humoral immunity), or both (Bellone, 2005; Fairweather, 2007). TLR on the surface of T and B cells are considered to play an important role in the initia-tion and progression of systemic autoimmune disease through recognition of exogenous and endogenous anti-gens (Marshak-Rothstein, 2006). DAMPs released during mitochondrial apoptosis such as oxidized mitochondrial DNA bind to NLR activating the inflammatory response through caspase-1 activation (Lopez-Armada et al., 2013). T cell-mediated damage to tissues occurs through the release of cytotoxic cytokines, prostaglandins, and reac-tive nitrogen and oxygen species. Individuals with bipolar disorder have a bias towards a Th1 pro-inflammatory pro-file and a reduced number of Treg cells, along with higher levels of senescence-associated cells such as CD8 and CD25 T cells (do Prado et al., 2012). The T cell system in bipolar disorder is activated in both symptomatic and euthymic patients with bipolar disorder (Breunis et al., 2003). Specific alterations in TLR agonist-mediated activ-ity were found in bipolar patients (McKernan et al., 2011). Infections are known to activate TLRs, and antibodies to toxoplasma and cytomegalovirus have been found in bipo-lar disorder patients (Tedla et al., 2011). Following TLR-mediated antigen recognition, GSK3 plays a crucial role in the immune response, and lithium is a GSK3 inhibitor capable of reducing inflammation (Beurel et al., 2010). The monocytes of a large proportion of bipolar patients and the offspring of bipolar parents show an inflammatory gene expression signature (Padmos et al., 2008) and are believed to arise from a shared environmental factor (Padmos et al., 2009). In addition to the enhancement of pro-inflammatory monocytes, Tregs are also enhanced in bipolar disorder, except in individuals with autoimmune thyroid disease or bipolar disorder who demonstrate a sig-nificantly reduced percentage of Tregs (Drexhage et al., 2011). In summary, abnormalities in T cells and cytokines involved in the Th1/Th2 balance show an imbalance (Brietzke et al., 2011; Kim et al., 2007) and may represent underlying T and B cell autoimmunity.

B cell-mediated immunity, however, occurs primarily through antibodies. IL-4 released by Th2 cells activates B cells to produce antibodies. In some individuals who are susceptible due to a breakdown in tolerance, B cells may produce self-reactive autoantibodies, which constitute the hallmark of autoimmune disease. Self-reactive antibodies can induce tissue damage by binding to self-tissues and activating complement-mediated damage, facilitating antibody-dependent cell-mediated cytotoxicity (ADCC), forming immune complexes, and initiating the comple-ment-induced lysis or removal of cells by phagocytic immune cells (Fairweather, 2007).

Thyroid autoimmunity has particularly been shown to be an independent risk factor for bipolar disorder with no association with lithium exposure (Haggerty Jr et al., 1990, 1997; Kupka et al., 2002), and it may serve as an endophe-notype for bipolar disorder (Vonk et al., 2007). Bipolar dis-order is associated with organ-specific autoimmunity to the antigens TPO, H/K ATPase, and GAD65, and the level of TPOAb is inversely correlated with the level of T cell acti-vation (Padmos et al., 2004). The female offspring of bipo-lar disorder patients are more vulnerable to developing thyroid autoimmunity, as evidenced by elevated TPOAb titres. However, TPOAb-positive offspring do not show an increased prevalence of mood disorders compared to TPOAb-negative offspring (Hillegers et al., 2007). Sidhom et al. (2012) have shown that patients with bipolar disorders have significantly more autoantibodies compared to people with other affective or psychotic disorders and non-psychi-atric controls. They concluded that a possible autoimmune activation occurs in at least a subgroup of psychiatric patients, particularly among those suffering from bipolar disorder. Spivak et al. (1996) found an increased frequency of antinuclear antibody (ANA) positivity in bipolar patients in comparison to controls, independent of any lithium ther-apy. Considering the above evidence, the association is strongest for thyroid autoimmunity, but its pathophysiology is uncertain and may be related to cross-reactivity with glu-tamate receptors (see later).

The role of CNS autoimmunity in bipolar disorder

The cells of the CNS innate immune system interact with T cells in the periphery to activate the adaptive immune sys-tem. Dendritic cells in the perivascular space and meninges can activate T cells in the periphery that then traverse the BBB. Once in the CNS, CD4 T cells can be restimulated by perivascular macrophages and dendritic cells, which act as antigen-presenting cells. T cells release Th1- and or Th2-type cytokines upon antigen recognition by TLRs and inter-act with microglia and astrocytes to amplify the immune response, resulting in the clearance of the offending antigen (Aloisi et al., 2000).

The inflamed brain provides a conducive environment for B cell survival and proliferation resulting in the produc-tion of antibodies (Corcione et al., 2005). B cells are known to cross the CNS and can initiate an autoimmune response against endogenous and exogenous ligands through mecha-nisms mentioned earlier (Meinl et al., 2006). The produc-tion of autoreactive antibodies against neuronal antigens (brain reactive antibodies) can interfere with neuronal transmission, prevent binding of neurotrophic factors such as brain-derived neurotrophic factor, and cause direct neu-ronal injury (Kapadia and Sakic, 2011). For example, autoantibodies directed against an epitope on the extracel-lular surface of oligodendrocytes can induce demyelination

Page 6: Immune dysregulation and autoimmunity in bipolar disorder ......clinical application Sanil Rege1,2,3 and Suzanne J Hodgkinson4,5 Abstract Objective: Increasing evidence suggests that

Rege and Hodgkinson 1141

Australian & New Zealand Journal of Psychiatry, 47(12)

either through activation of complement or through their recognition by Fc-receptors of activated macrophages (Bradl and Lassmann, 2010). T and B cell autoimmunity can be triggered through several mechanisms. PAMPs can cross-react with self-epitopes through a process of molecu-lar mimicry (Chastain and Miller, 2012). Secondly, cell injury in the CNS can result in the release of DAMPs that can become immunogenic, initiating a T cell autoimmune response against self-antigens (Harris and Fabry, 2012). Extracellular mitochondrial DNA is known to be extremely immunogenic and can directly initiate an autoimmune response (Zhang et al., 2010). Cross-reactivity with self-antigens can initiate an autoimmune reaction against neu-ronal antigens. For example, a subset of the anti-DNA antibody is known to cross-react with the NR2 glutamate receptor (DeGiorgio et al., 2001); elevated serum antibod-ies to the NR2 subunit of the glutamate receptor are found in the acute phase of mania (Dickerson et al., 2012). Some DAMPs, such as S100B, extracellular nucleotides, and extracellular matrix components of basement membrane are plausible candidates in the initiation of autoimmune response. Furthermore, microscopic particles have been found in the CSF of individuals with bipolar disorder and only rarely in controls. It is unclear whether these particles represent DAMPs, and further research is required to clar-ify this (Johansson et al., 2012). Kapadia and Sakic (2011) have integrated the CNS innate and adaptive immune sys-tem mechanisms by proposing two phases, the inflamma-tory phase, which is dominated by innate immunity and leads to functional damage, followed by the autoimmune phase, which is responsible for structural damage such as neurodegeneration and atrophy. CNS T and B cell autoim-munity is an underexplored area in bipolar disorder. It should be noted that endogenous protective regulatory sig-nals, such as Treg cells and B cell-mediated immunoregula-tion, exist in the brain to prevent autoimmune responses and that the dysregulation of such mechanisms may be responsible for initiating and promoting autoimmune responses (Block et al., 2007; Goverman, 2009).

Autoimmune disorders and bipolar disorder: focus on neuropsychiatric lupus erythematosus, anti-NMDA encephalitis, and Hashimoto’s encephalopathy

A large Danish cohort study showed that autoimmune pro-cesses precede the onset of bipolar disorder (Eaton et al., 2010). Although research on the link between autoimmune diseases and psychiatric disorders is at a relatively early stage, autoimmune diseases, such as autoimmune synaptic encephalitis, neuropsychiatric systemic lupus erythemato-sus (NPSLE), and encephalopathy associated with autoim-mune thyroiditis (EAAT), particularly Hashimoto’s

encephalopathy, have been studied in greater depth by rheumatologists and neurologists. Although case reports of other autoimmune diseases presenting with symptoms of bipolar disorder exist, we focus on these three disorders due to their high biological plausibility of being related to the pathophysiology of bipolar symptoms based on evidence of involvement of the glutamate pathway. Thus, these should be considered high on the differential diagnosis list when autoimmunity is suspected in psychiatry. The three autoim-mune disorders are summarized in Table 1.

Among the best-known and most well-studied condi-tions is NPSLE. The prevalence of neuropsychiatric mani-festations in SLE is estimated to range from 14% to 80% in adults and from 22% to 95% in children (Muscal and Brey, 2010; Popescu and Kao, 2011). There have been case reports of NPSLE presenting as bipolar disorder (Alao et al., 2009; Yeh and Hu, 2007). The most common symp-toms in NPSLE include the following: cognitive dysfunc-tion (75–80%), mood disorders (69–74%), headache (39–61%), seizures (8–18%), cerebrovascular disease (2–8%), psychosis (3–5%), cranial neuropathy (1.5–2.1%), and movement disorders (1%). These symptoms indicate that NPSLE may present to psychiatrists first (Popescu and Kao, 2011). Cytokines and chemokines play key roles in the pathogenesis of NPSLE (Okamoto et al., 2010). A key effector mechanism in NPSLE in the development of cog-nitive dysfunction and mood disorders may be the gluta-matergic pathway through the NMDA receptors situated in the hippocampus, frontal regions, and limbic system (Mak et al., 2009). dsDNA antibody is an important antibody in this respect due to its cross-reactivity with the NR2 gluta-mate receptor (DeGiorgio et al., 2001). The pathogenesis of NPSLE is multifactorial and is shown in Figure 1.

The diagnosis of neuropsychiatric lupus in clinical prac-tice is a contentious issue amongst psychiatrists, rheuma-tologists, and other caregivers. Standard laboratory testing and imaging studies may not always detect active brain dis-ease or static damage (Wright, 2010). Thus, it is important for psychiatrists to be aware of the limitations in diagnostic criteria and the potential management issues they face. There is no single diagnostic test for SLE, and the American College of Rheumatology criteria are intended for classifi-cation rather than diagnosis (Hughes, 1998). ANA and dsDNA antibody are sensitive and specific serological markers, respectively, for SLE. The application of the NPSLE criteria in psychiatry is limited by the requirement of a temporal relationship between SLE and a psychiatric disorder (SLE before neuropsychiatric presentation); this contradicts evidence showing that the brain may be affected early in SLE with primary neuropsychiatric presentations, even before a diagnosis of SLE is made, and neither a nor-mal erythrocyte sedimentation rate nor negative serology excludes CNS lupus (Joseph et al., 2007; Petri et al., 2008). Moreover, NPSLE manifestations have been found to be negatively correlated with systemic manifestations such as

Page 7: Immune dysregulation and autoimmunity in bipolar disorder ......clinical application Sanil Rege1,2,3 and Suzanne J Hodgkinson4,5 Abstract Objective: Increasing evidence suggests that

1142 ANZJP Articles

Australian & New Zealand Journal of Psychiatry, 47(12)

Table 1. Summary of important autoimmune disorders presenting with psychiatric symptoms.

Condition Clinical features Investigations Pathogenesis Treatment

Anti-NMDA Encephalitis

80% women Antineuronal antibodies Anti-NMDA antibodies against the NR1 subunit

IV methylprednisone

Other antibodies against synaptic antigens: Anti-Hu, Anti-MaAnti-CRMP-5 and CV2Anti-VgKCAnti-AMPA Anti-GABA-B

Any age group MRI: T2 or FLAIR signal in medial temporal lobes (15%); normal in >50%

Immunosuppressants

Symptoms preceded by prodromal viral illness or URTI

EEG: Non-specific slow, disorganized activity, sometimes with seizure activity

IV IgG

Psychosis, memory deficits, confusion, dyskinesia, seizures, autonomic instability

CSF: lymphocytic pleiocytosis (80%)

Cyclophosphamide and ritumixab

Associated with tumour in some casesa

NPSLE Female:male ratio 9:1 ANA, dsDNA antibody See Figure 2 Psychotropics Women in

childbearing yearsAntineuronal antibodies, anti-phospholipid antibodies

Steroids

Cognitive dysfunction EEG: non-specific generalized or focal slowing/seizures or seizure-like activity

NSAIDs

Mood disorder MRI: multiple discrete white-matter lesions in periventricular and subcortical white matter (40–80%)

Hydroxychloroquine

Headache FDG PET: parieto-occipital white matter hypometabolism (60–80%)

Immunosuppressants

Seizures SPECT: areas of hypoperfusion

Antiplatelet agents and anticoagulation

CVD Psychosis Cranial neuropathy Movement disorder Features of SLE

Encephalopathy associated with autoimmune thyroiditis (Hashimoto’s encephalopathy)

Fifth and sixth decade of life80% female patientsCognitive impairmentSeizures

Anti-TPOAnti-thyroglobulin (TgAb)CSF: lymphocytic pleiocytosis (80%)EEG: generalized slowing/FIRDA/focal slow waves/epileptiform discharges

Autoimmune cerebral vasculitisAntibodies against amino terminus of alpha enolase (NAE)Intrathecal thyroid antibodiesGlobal cerebral hypoperfusion

IV methylprednisone (1 g/kg)Oral prednisone (1–2 mg/kg)Immunosuppressive drugsGood response to steroids

(Continued)

Page 8: Immune dysregulation and autoimmunity in bipolar disorder ......clinical application Sanil Rege1,2,3 and Suzanne J Hodgkinson4,5 Abstract Objective: Increasing evidence suggests that

Rege and Hodgkinson 1143

Australian & New Zealand Journal of Psychiatry, 47(12)

Figure 1. The pathogenic mechanism of autoantibodies is related to the breakdown of the blood–brain barrier and CSF autoantibodies forming and binding to the cell antigens that are released by neurocytotoxic antibodies (e.g. anti-ribosomal P, anti-NR2), which form immune complexes and stimulate production of IFN-α and pro-inflammatory cytokines and chemokines (Fragoso-Loyo et al., 2007; Santer et al., 2009). IFN-α is thought to be the effector mechanism of cognitive and mood effects in NPSLE. Thus, serum antibodies of SLE (antinuclear antibody and dsDNA antibody) may not be reliable markers of neuropsychiatric disease, as there is a lack of correlation between serum autoantibodies and NPSLE manifestations, and neuropsychiatric manifestations may be mediated by alternate antibodies, such as NR2 glutamate-receptor antibodies that cross-react with anti-DNA antibodies (Arinuma et al., 2008; DeGiorgio et al., 2001; Omdal et al., 2005).

Condition Clinical features Investigations Pathogenesis Treatment

Behavioural disorders MRI: normal in 50% of cases, T2 high-intensity signal

Anti-GluRε2 antibodies

Myoclonus Ataxia Dysphasia Aphasia Confusion Tremor Psychosis Headache

aOver 50% of cases are not associated with a neoplasm.CSF, cerebrospinal fluid; CVD, cardiovascular disease; EEG, electroencephalography; FDG PET, fluorodeoxyglucose positron emission tomography; MRI, magnetic resonance imaging; NSAID, nonsteroidal anti-inflammatory drug; SPECT, single-photon emission computed tomographySource: Castillo et al. (2006); de Hollanda (2011); Kayser et al. (2010); Popescu and Kao (2011); and Brey and Muscal (2010).

Table 1. (Continued)

joint and skin involvement in children and adults (Harel et al., 2006; Karassa et al., 2000), and the American College of Rheumatology criteria may be biased towards more

severe disease and a longer duration of disease and do not reflect clinical diagnoses as assigned by lupus experts (Wallace and Hahn, 2006). Thus, clinical diagnostic

Page 9: Immune dysregulation and autoimmunity in bipolar disorder ......clinical application Sanil Rege1,2,3 and Suzanne J Hodgkinson4,5 Abstract Objective: Increasing evidence suggests that

1144 ANZJP Articles

Australian & New Zealand Journal of Psychiatry, 47(12)

impressions in NPSLE must be based on the combined use of immunoserological testing, functional and/or structural neuroimaging, and standardized neurological, rheumato-logical, psychiatric, and neuropsychological assessments (Hermosillo-Romo and Brey, 2002). These findings show that the current criteria for NPSLE diagnosis and their gen-eralizability to psychiatric patients should be examined in view of the high degree of morbidity and mortality associ-ated with NPSLE (Monov and Monova, 2008). The major histocompatability complex located on chromosome 6 pro-vides further support for the association between bipolar disorder and NPSLE: the genes in this region have been implicated in bipolar disorder and provide a strong genetic association with a range of autoimmune disorders, particu-larly SLE (Harley, 2002; International Schizophrenia Consortium et al., 2009; Jonsen et al., 2004).

The identification of encephalitis associated with antibod-ies against cell surface and synaptic antigens has had a sub-stantial impact in neuropsychiatry. Classically, encephalitis due to synaptic antibodies evolves over days to weeks and includes psychiatric manifestations as diverse as irritability, mood disturbance, hallucinations, and personality distur-bances. Further neurocognitive changes occur in the form of short-term memory loss, sleep disturbances, and seizures. Anti-NMDA encephalitis is of particular relevance to psy-chiatrists due to its clinical presentation. Over 200 patients

with anti-NMDA encephalitis have been described, and 75% present initially to psychiatrists (Kayser et al., 2010). The antibody in anti-NMDA encephalitis specifically recognizes the NR1 subunit of the NMDA receptor, which is present in all NMDA receptors (Dalmau et al., 2008). In contrast, the antineuronal antibodies in NPSLE recognize the NR2A and NR2B subunits of the NMDA receptor, which are highly con-centrated in the hippocampus (Kayser and Dalmau, 2011). These differences in location and antigenic targets may explain the difference in presentation between NPSLE and anti-NMDA encephalitis. Recently, antineuronal antibodies, which are characteristic of synaptic encephalitis, have been considered important biomarkers in NPSLE (Gorman, 2011).

EAAT is the third important differential. In the context of encephalopathy, anti-TPO antibodies are used to diag-nose Hashimoto’s encephalopathy (Mocellin et al., 2007). Reports exist of Hashimoto’s encephalopathy presenting with depression, mania, and cognitive dysfunction (Bochetta et al., 2007; Canelo-Aybar et al., 2011; Liu et al., 2011a; Mussig et al., 2005). This disorder is also termed steroid-responsive EAAT due to its often-dramatic response to steroids (Castillo et al., 2006). Despite concerns regard-ing steroid use in psychosis, a good response to steroids has been obtained in psychosis associated with autoimmune thyroiditis, implying an immunological pathogenesis (Arrojo et al., 2007; Gómez-Bernal et al., 2007). A recent

Table 2. Clinical indicators that should raise suspicion of autoimmunity in practice.

Neuropsychiatric Others

Treatment resistance or progression despite therapeutic doses of psychotropics

Arthritis

Atypical psychiatric presentations Facial erythematous rash/discoid rash/photosensitivity

Stroke/transient ischaemic attack Kidney disease

Headache/migraine Recurrent miscarriages

Cognitive dysfunction Hypo/hyperthyroidism

Movement disorder (chorea, dystonia, Parkinsonism, catatonia)

Family history of autoimmunity

Seizures Viral prodrome

Fluctuating presentation Significantly elevated ANA and dsDNA antibody

Acute behavioural/personality change T2 and FLAIR signal abnormalities on MRI

Neuropathy Abnormal EEG

A number of the above symptoms should prompt serological testing and investigations for autoimmune disease. The symptoms could be present at any time in a person’s life; hence, a medical history (current and past) and medical examination are important

Elevated ANA is useful in confirming suspicions, but a negative ANA or dsDNA antibody does not rule out autoimmunity or NPSLE. The test for ANAs has a very high diagnostic sensitivity, such that it is considered the best test for the screening for systemic autoimmune diseases but caution is to be exercised and recommendations are that tests to detect autoantibodies are performed only when a consistent clinical suspicion of autoimmune disease is present (Tozzoli et al., 2002)

ANA, antinuclear antibody.

Page 10: Immune dysregulation and autoimmunity in bipolar disorder ......clinical application Sanil Rege1,2,3 and Suzanne J Hodgkinson4,5 Abstract Objective: Increasing evidence suggests that

Rege and Hodgkinson 1145

Australian & New Zealand Journal of Psychiatry, 47(12)

study showed that anti-GluRε2 antibodies may be associ-ated with the neuropsychiatric manifestations of psychiat-ric patients with antithyroid antibodies (Chiba et al., 2012). The treatment response to immunomodulation in these patients has not been studied.

In Table 2, we present a list of clinical features based on a review of the important autoimmune conditions described above that can help increase the detection of autoimmunity in psychiatry. Although this list has not yet been validated to any degree, it may help clinicians to suspect autoimmun-ity and form a basis for further research. The detailed treat-ment of each disorder is outside the scope of the article and includes a combination of psychotropics, corticosteroids, and immunosuppressants that is summarized in Table 1.

Thus, NPSLE, some forms of autoimmune encephalitides, and some subsets of bipolar disorder presentations may have common underlying pathophysiological mechanisms.

The role of stress and its interaction with the immune system

A stressful event is often associated with bipolar disorder presentations. There are no specific studies examining the role of stress, immune dysregulation, and autoimmunity in bipolar disorder, and we discuss this association in general terms. The link between stress and mood disorders is well recognized, with corticotrophin-releasing hormone playing an important role in the pathophysiology (Stout and Nemeroff, 1994). Retrospective studies in autoimmune dis-eases have found that up to 80% of patients report uncom-mon emotional stress before disease onset (Stojanovich and Marisavljevich, 2008). Psychosocial stressors activate cor-ticotrophin-releasing hormone and the sympathetic nervous system, increasing NF-KB DNA binding in inflammatory cells and resulting in the release of cytokines that act through the pathways described earlier. Pro-inflammatory cytokines then induce cortisol release, which aims to decrease the inflammatory response. This pathway is down-regulated in chronic stress, resulting in an imbalance between pro-inflammatory and anti-inflammatory cytokines (Miller et al., 2009). Furthermore, there is evi-dence that brief naturalistic stressors, such as academic exams, potentiate a shift towards a Th2 response, whereas chronic stress reduces both Th1 and Th2 responses (Plotnikoff, 2007; Segerstrom and Miller, 2004). Figure 2 synthesizes this evidence to propose a hypothesis of the interaction between stress/trauma, cytokines, the hypotha-lamic–pituitary–adrenal axis, autoimmunity, and the brain in the pathogenesis of psychiatric symptoms. The model is complicated by other triggers, such as physical CNS injury and infections, both of which can activate autoimmunity. This model can be extrapolated to other psychiatric disor-ders. We refer readers to Plotnikoff (2007) and Segerstrom and Miller (2004) for a more detailed explanation on the role of stress and the immune system.

Future research and implications for clinical practice

A limitation in the existing literature examining cytokines and bipolar disorder is the cross-sectional nature of the stud-ies. It is unclear if the cytokine dysfunction represents a true causal mechanism in the pathophysiology of bipolar disor-der, is an epiphenomenona, or is related to medication (Langan and McDonald, 2009). It may also represent under-lying T and B cell autoimmunity. It is also too early to com-ment on the relationship of autoimmunity with the pathophysiology of bipolar disorder. Identifying specific autoantibodies in varying phases of the illness may be one way forward (antibodies to 5-HT and anchorage molecules as found in depression; Maes et al., 2011, 2012b). Antibodies against NMDARs merit further investigation in bipolar dis-order. Future research should include autoantibodies and inflammatory markers as biomarkers in addition to clinical features and neuroimaging with the aim of stratifying psy-chiatric presentations. This is in line with proposals by Kapur et al. (2012) for “stratified psychiatry”, which will improve clinical outcomes across conventional diagnostic boundaries. With the advent of neuroimaging techniques such as two-/multiphoton and fluorescence microscopy, existing nuclear medicine techniques with radiolabelled ligands for cells involved in neuroinflammation, and tech-niques to visualize T cell movement and migration, further advances will result in an improved understanding of the role of neuroinflammation in psychiatric disorders.

Current research examining the link between autoim-mune diseases and psychiatry may be susceptible to referral and spectrum bias. Longitudinal prospective cohort studies are required to establish the pathogenesis of the neuropsychi-atric autoimmune disease process and evaluate the interven-tions that are appropriate. There is a case for multispecialty collaboration in research projects due to the multisystem involvement of autoimmune diseases. In clinical practice, the diagnosis of autoimmune encephalopathy requires a high index of clinical suspicion, as tests including serology, EEG, CSF, and MRI can be normal and do not exclude an autoim-mune pathology. Psychiatrists should pay particular attention to the milder incomplete cases of anti-NMDA encephalitis (formes frustes), which may continue to be treated as psychi-atric disorders (Dalmau et al., 2011). Clues to autoimmune encephalopathies often lie in the longitudinal history. Movement disorders, cognitive dysfunction, and fluctuating cognition are common in all three autoimmune encephalopa-thies and can be attributed incorrectly to antipsychotic medi-cation, thus creating a protopathic bias. A detailed medical evaluation (history and examination), cognitive examina-tion, case-note review, and corroborative history taking from the family are important in psychiatric evaluations, particu-larly in atypical presentations characterized by a non-response or poor response to psychotropics. Based on advice by Neuwelt and Young (2009), the management of

Page 11: Immune dysregulation and autoimmunity in bipolar disorder ......clinical application Sanil Rege1,2,3 and Suzanne J Hodgkinson4,5 Abstract Objective: Increasing evidence suggests that

1146 ANZJP Articles

Australian & New Zealand Journal of Psychiatry, 47(12)

autoimmune encephalopathies requires a team approach, including a rheumatologist, neurologist, neuroimmunologist, psychiatrist, neuropsychologist, oncologist, and primary-care physician, to formulate a proper diagnosis and treatment plan for the management of NPSLE.

From a treatment perspective, the consideration of the immune hypothesis opens up a new avenue for research into the role of immunomodulators in psychiatry. Although this review cannot make conclusive treatment recommenda-tions, there is a case for an empirical trial of

Figure 2. The role of stress and its interaction with the immune system. Stress and trauma lead to activation of cytokine and cortisol release which lead to an adaptive T cell response to external or internal antigens (Segerstrom and Miller, 2004). Cortisol acts by reducing inflammatory tissue damage due to inflammatory cytokines. The cortisol release is modulated by the hypothalamic–pituitary–adrenal axis feedback mechanism to avoid prolonged cortisol release. In chronic stress, however, prolonged elevated cortisol release leads to downregulation of cortisol receptors on T lymphocytes resulting in unrestricted tissue damage and amplification of the immune response resulting in autoimmunity in susceptible individuals (Cohen et al., 2012). This susceptibility is governed by genes, environmental factors, or hormonal factors. The activation of autoimmunity and cytokine release can result in endothelial cell damage at the level of the blood–brain barrier resulting in passage of cytokines through the blood–brain barrier. Cytokines then act on the brain though various mechanisms resulting in the genesis of psychiatric symptomatology. SERT, serotonin transporter; IDO, indoleamine 2,3-dioxygenase.

Page 12: Immune dysregulation and autoimmunity in bipolar disorder ......clinical application Sanil Rege1,2,3 and Suzanne J Hodgkinson4,5 Abstract Objective: Increasing evidence suggests that

Rege and Hodgkinson 1147

Australian & New Zealand Journal of Psychiatry, 47(12)

steroids in suspected cases of immune-related psychiatric encephalopathy after excluding infections, as in cases of limbic encephalitis and steroid-responsive EAAT (Bataller et al., 2007; Castillo et al., 2006). It is important that the psychiatrist be familiar with steroid administration and its side effects. Knight et al. (2007) have noted that concerns about corticosteroids in psychiatry are not well founded and are based primarily on anecdotal evidence. The prescription of psychotropics in the context of organic brain disease can increase morbidity, mortality, and the risk of Neuroleptic Malignant Syndrome (NMS) (Adnet et al., 2000; Maat et al., 2012), notwithstanding the morbidity and mortality from untreated conditions such as NPSLE (Yu et al., 2006) and autoimmune synaptic encephalitis. Thus, a careful, individualized risk–benefit analysis is required. Among psy-chotropics, lithium and clozapine (used in certain treatment-resistant illnesses) have immunosuppressive properties (Beurel et al., 2010; Boufidou et al., 2004; Knight et al., 2007; Maes et al., 2007) that possibly contribute to their superiority in treatment-resistant cases; however, their use in autoimmune encephalopathies has not been evaluated. The use of anti-inflammatory medications is also known to restore adult hippocampal neurogenesis and thus has the potential to improve cognitive deficits (Monje et al., 2003). Existing cytokine inhibitors (anti-TNF-α), such as etaner-cept, adalimumab, and infliximab, are used in the manage-ment of rheumatoid arthritis and psoriasis and have been shown to both relieve the symptoms of psoriasis and improve affective, somatic, and cognitive functions (Soczynska et al., 2009; Tyring et al., 2006), but they have not been evaluated in primary psychiatric presentations. The role of smoking cessation and addressing alcohol misuse should not be overlooked, as smoking is a direct contribu-tory factor to the passage of cytokines through the BBB, and alcohol exerts pro-apoptotic effects on neuronal cells (Valles et al., 2004). Omega-3 fatty acids, N-acetyl cysteine, statins, coenzyme Q10, lipoic acid, curcuma, and TNF inhibitors are potential therapeutic neuroprotective factors acting on inflammatory, apoptotic, and oxidative pathways (Berk et al., 2011). Future treatments could include medications that act on neuroinflammatory pathways.

The roles of stress and trauma in immunity and autoim-munity offer new opportunities for research in patients with borderline personality disorder (BPD), post-traumatic stress disorder (PTSD), and traumatic brain injury. In BPD, the links with thyroid antibodies (Geracioti et al., 2003), increased pro-inflammatory cytokines (Kahl et al., 2006) and high rates (30–84%) of diffuse slow-wave and spike-wave EEG abnormalities (Boutros et al., 2003) raise the question of whether BPD is a form of chronic subacute encephalopathy that is related to autoimmunity. In PTSD, cortisol treatment has been proposed to ameliorate the intensity of intrusive memories and might also be useful in preventing low-grade systemic inflammation, which in turn, is discussed as a pathophysiological mechanism

underlying somatic symptoms in PTSD through the cytokine pathway (Aerni et al., 2004; Rohleder et al., 2009). Traumatic brain and spinal injuries are associated with anti-body production, which is responsible for a range of somatic symptoms that cannot be explained purely by neu-rological injury (Ankeny and Popovich, 2010).

Conclusions

The link between immune dysregulation, autoimmunity, and psychiatric illness may be closer than previously thought. The identification of aetiological markers to guide treatment has largely eluded psychiatrists. With the advent of sophisticated neuroimaging techniques and immunologi-cal markers, psychiatrists will be able to identify subsets of disorders that have an immunological basis. This review adds to the increasing body of evidence suggesting that immune dysregulation, neuroinflammation, and autoim-munity may play an important role in psychiatric disorders. NPSLE, anti-NMDA encephalitis, and EAAT are important differentials for the psychiatrist to consider when suspecting autoimmune encephalopathy. Even if the autoimmune dis-ease is not directly aetiologically related to the psychiatric presentation, its detection is important due to the high mor-bidity and mortality associated with autoimmune diseases. Early intervention could result in a significant decrease in morbidity for patients and in cost savings for services by preventing multisystem involvement in the future.

In the end, it is clear that if the understanding of a dis-ease is to be furthered in the 21st century, the current Cartesian mind–body dichotomy is an untenable paradigm, just as Plato discovered over 2000 years ago.

Acknowledgements

We would like to thank Professor David Castle and Professor Philip Boyce for their criticism and comments in the preparation of this manuscript.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Declaration of interest

SR is a founding trainer at Psych Scene, a company providing educational courses for psychiatry exams. SJH reports no conflict of interest. The authors alone are responsible for the content and writing of the paper.

ReferencesAdnet P, Lestavel P and Krivosic-Horber R (2000) Neuroleptic malignant

syndrome. British Journal of Anaesthesia 85: 129–135.Aerni A, Traber R, Hock C, et al. (2004) Low-dose cortisol for symp-

toms of posttraumatic stress disorder. American Journal of Psychiatry 161:1488–1490.

Page 13: Immune dysregulation and autoimmunity in bipolar disorder ......clinical application Sanil Rege1,2,3 and Suzanne J Hodgkinson4,5 Abstract Objective: Increasing evidence suggests that

1148 ANZJP Articles

Australian & New Zealand Journal of Psychiatry, 47(12)

Alao AO, Chlebowski S and Chung C (2009) Neuropsychiatric systemic lupus erythematosus presenting as bipolar I disorder with catatonic features. Psychosomatics 50: 543–547.

Aloisi F, Ria F and Adorini L (2000) Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astro-cytes. Immunology Today 21: 141–147.

Andreazza AC, Kauer-Sant’Anna M, Frey BN, et al. (2008) Oxidative stress markers in bipolar disorder: a meta-analysis. Journal of Affective Disorders 111: 135–144.

Ankeny DP and Popovich PG (2010) B cells and autoantibodies: complex roles in CNS injury. Trends in Immunology 31: 332–338.

Arinuma Y, Yanagida T and Hirohata S (2008) Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis and Rheumatism 58: 1130–1135.

Arrojo M, Perez-Rodriguez MM, Mota M, et al. (2007) Psychiatric pres-entation of Hashimoto’s encephalopathy. Psychosomatic Medicine 69: 200–201.

Bataller L, Kleopa KA, Wu GF, et al. (2007) Autoimmune limbic enceph-alitis in 39 patients: immunophenotypes and outcomes. Journal of Neurology, Neurosurgery and Psychiatry 78: 381–385.

Bellone M (2005) Autoimmune disease: pathogenesis. Hoboken, NJ: Wiley.

Benes FM, Matzilevich D, Burke RE, et al. (2006) The expression of proa-poptosis genes is increased in bipolar disorder, but not in schizophre-nia. Molecular Psychiatry 11: 241–251.

Berk M, Kapczinski F, Andreazza AC, et al. (2011) Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxida-tive stress and neurotrophic factors. Neuroscience and Biobehavioral Reviews 35: 804–817.

Beurel E, Michalek SM and Jope RS (2010) Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends in Immunology 31: 24–31.

Block ML, Zecca L and Hong JS (2007) Microglia-mediated neuro-toxicity: uncovering the molecular mechanisms. Nature Reviews Neuroscience 8: 57–69.

Bochetta A, Tamburini G, Cavolina P, et al. (2007) Affective psychosis, Hashimoto’s thyroiditis, and brain perfusion abnormalities: case report. Clinical Practice and Epidemiology in Mental Health 3: 31.

Boufidou F, Nikolaou C, Alevizos B, et al. (2004) Cytokine production in bipolar affective disorder patients under lithium treatment. Journal of Affective Disorders 82: 309–313.

Boutros NN, Torello M and McGlashan TH (2003) Electrophysiological aberrations in borderline personality disorder: state of the evidence. Journal of Neuropsychiatry and Clinical Neurosciences 15, 145–154.

Bradl M and Lassmann H (2010) Oligodendrocytes: biology and pathol-ogy. Acta Neuropathologica 119: 37–53.

Breunis MN, Kupka RW, Nolen WA, et al. (2003) High numbers of cir-culating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biological Psychiatry 53: 157–165.

Brietzke E and Kapczinski F (2008) TNF-α as a molecular target in bipo-lar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32: 1355–1361.

Brietzke E, Kauer-Sant’Anna M, Teixeira AL, et al. (2009) Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain, Behavior and Immunity 23: 1079–1082.

Brietzke E, Stabellini R, Grassis-Oliveira R, et al. (2011) Cytokines in bipolar disorder: recent findings, deleterious effects but promise for future therapeutics. CNS Spectrums 16: 157–168.

Canelo-Aybar C, Loja-Oropeza D, Cuadra-Urteaga J, et al. (2011) Hashimoto’s encephalopathy presenting with neurocognitive symp-toms: a case report. Journal of Medical Case Reports 4, 337.

Capuron L, Pagnoni G, Demetrashvili M, et al. (2005) Anterior cingu-late activation and error processing during interferon-alpha treatment. Biological Psychiatry 58: 190–196.

Capuron L, Pagnoni G, Demetrashvili MF, et al. (2007) Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology 32: 2384–2392.

Castillo P, Woodruff B, Caselli R, et al. (2006) Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Archives of Neurology 63: 197–202.

Chang CC, Shiah IS, Chen CL, et al. (2005) Bipolar disorder induced by resuming interferon-alpha treatment in a patient with chronic hepatitis B. Journal of Medical Sciences 25: 101–104.

Chastain EM and Miller SD (2012) Molecular mimicry as an inducing trigger for CNS autoimmune demyelinating disease. Immunological Reviews 245: 227–238.

Chiba Y, Katsuse O, Takahashi Y, et al. (2012) Anti-glutamate receptor ε2 antibodies in psychiatric patients with anti-thyroid autoantibodies – a prevalence study in Japan. Neuroscience Letters 534: 217–222.

Clay HB, Sillivan S and Konradi C (2011) Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. International Journal of Developmental Neuroscience 29: 311–324.

Cohen S, Janicki-Deverts D, Doyle WJ, et al. (2012) Chronic stress, glucocor-ticoid receptor resistance, inflammation, and disease risk. Proceedings of the National Academy of Sciences, USA 109: 5995–5999.

Constant A, Castera L, Dantzer R, et al. (2005) Mood alterations during interferon-alpha therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. Journal of Clinical Psychiatry 66: 1050–1057.

Corcione A, Aloisi F, Serafini B, et al. (2005) B-cell differentiation in the CNS of patients with multiple sclerosis. Autoimmunity Reviews 4: 549–554.

Daban C, Vieta E, Mackin P, et al. (2005) Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatric Clinics of North America 28: 469–480.

Dalmau J, Gleichman AJ, Hughes EG, et al. (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurology 7: 1091–1098.

Dalmau J, Lancaster E, Martinez-Hernandez E, et al. (2011) Clinical expe-rience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurology 10: 63–74.

Dantzer R, Konsman JP, Bluthé RM, et al. (2000) Neural and humoral pathways of communication from the immune system to the brain: parallel or convergent? Autonomic Neuroscience 85: 60–65.

Das S and Basu A (2007) Inflammation: a new candidate in modulating adult neurogenesis. Journal of Neuroscience Research 86: 1199–1208.

Davison K (2012) Autoimmunity in psychiatry. British Journal of Psychiatry 200: 353–355.

DeGiorgio LA, Konstantinov KN, Lee SC, et al. (2001) A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nature Medicine 7: 1189–1193.

Dickerson F, Stallings C, Vaughan C, et al. (2012) Antibodies to the gluta-mate receptor in mania. Bipolar Disorders 14: 547–553.

do Prado CH, Rizzo LB, Wieck A, et al. (2012) Reduced regulatory T cells are associated with higher levels of Th1/TH17 cytokines and acti-vated MAPK in type 1 bipolar disorder. Psychoneuroendocrinology 38: 667–676.

Drexhage RC, Hoogenboezem TH, Versnel MA, et al. (2011) The activa-tion of monocyte and T cell networks in patients with bipolar disorder. Brain, Behavior and immunity 25: 1206–1213.

Dugan LL, Sensi SL, Canzoniero LM, et al. (1995) Mitochondrial produc-tion of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate. Journal of Neuroscience 15: 6377–6388.

Dunn AJ (2000) Cytokine activation of the HPA axis. Annals of the New York Academy of Sciences 917: 608–617.

Eaton WW, Pedersen MG, Nielsen PR, et al. (2010) Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disorders 12: 638–646.

Edgar N and Sibille E (2012) A putative functional role for oligodendro-cytes in mood regulation. Translational psychiatry 2: e109.

Fairweather D (2007) Autoimmune disease: mechanisms. Hoboken, NJ: Wiley.

Fan X, Goff DC and Henderson DC (2007) Inflammation and schizophre-nia. Expert Review of Neurotherapeutics 7: 789–796.

Page 14: Immune dysregulation and autoimmunity in bipolar disorder ......clinical application Sanil Rege1,2,3 and Suzanne J Hodgkinson4,5 Abstract Objective: Increasing evidence suggests that

Rege and Hodgkinson 1149

Australian & New Zealand Journal of Psychiatry, 47(12)

Fearon DT and Locksley RM (1996) The instructive role of innate immu-nity in the acquired immune response. Science 272: 50–53.

Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narvaez A, et al. (2007) Interleukin-6 and chemokines in the neuropsychiatric manifesta-tions of systemic lupus erythematosus. Arthritis and Rheumatism 56: 1242–1250.

Geracioti TD Jr, Kling MA, Post RM, et al. (2003) Antithyroid antibody-linked symptoms in borderline personality disorder. Endocrine 21: 153–158.

Gidron Y, Kupper N, Kwaijtaal M, et al. (2007) Vagus-brain communica-tion in atherosclerosis-related inflammation: a neuroimmunomodula-tion perspective of CAD. Atherosclerosis 195: e1–e9.

Gigante AD, Bond DJ, Lafer B, et al. (2012) Brain glutamate levels meas-ured by magnetic resonance spectroscopy in patients with bipolar dis-order: a meta-analysis. Bipolar Disorders 14: 478–487.

Gómez-Bernal GJ, Reboreda A, Romero F, et al. (2007) A case of Hashimoto’s encephalopathy manifesting as psychosis. Primary Care Companion to the Journal of Clinical Psychiatry 9: 318–319.

Goodnow CC (2007) Multistep pathogenesis of autoimmune disease. Cell 130: 25–35.

Gorman M (2011) Will anti-neuronal antibody biomarkers make neu-ropsychiatric systemic lupus erythematosus no longer a diagnosis of exclusion? Developmental Medicine and Child Neurology 53: 483.

Goverman J (2009) Autoimmune T cell responses in the central nervous system. Nature Reviews Immunology 9: 393–407.

Haggerty JJ Jr, Evans DL, Golden RN, et al. (1990) The presence of antithyroid antibodies in patients with affective and nonaffective psy-chiatric disorders. Biological Psychiatry 27: 51–60.

Haggerty JJ Jr, Silva SG, Marquardt M, et al. (1997) Prevalence of antithyroid antibodies in mood disorders. Depression and Anxiety 5: 91–96.

Harel L, Sandborg C, Lee T, et al. (2006) Neuropsychiatric manifesta-tions in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. Journal of Rheumatology 33: 1873–1877.

Harley JB (2002) The genetic etiology of systemic lupus erythematosus: a short dispatch from the combat zone. Genes and Immunity 3, S1–4.

Harris MG and Fabry Z (2012) Initiation and regulation of CNS auto-immunity: balancing immune surveillance and inflammation in the CNS. Neuroscience and Medicine 3: 203–224.

Hashimoto K, Sawa A and Iyo M (2007) Increased levels of glutamate in brains from patients with mood disorders. Biological Psychiatry 62:1310–1316.

Hermosillo-Romo D and Brey RL (2002) Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Best Practice and Research. Clinical Rheumatology 16: 229–244.

Hillegers MH, Reichart CG, Wals M, et al. (2007) Signs of a higher preva-lence of autoimmune thyroiditis in female offspring of bipolar par-ents. European Neuropsychopharmacology 17: 394–399.

Hu S, Peterson PK and Chao CC (1997) Cytokine-mediated neuronal apoptosis. Neurochemistry International 30: 427–431.

Huang EJ and Reichardt LF (2001) Neurotrophins: roles in neuronal devel-opment and function. Annual Review of Neuroscience 24: 677–736.

Hughes GRV (1998) Is it lupus? The St. Thomas’ Hospital “alternative” criteria. Clinical and Experimental Rheumatology 16: 250–252.

Iancu I, Sverdlik A, Dannon PN, et al. (1997) Bipolar disorder associ-ated with interferon-alpha treatment. Postgraduate Medical Journal 73: 834.

International Schizophrenia Consortium, Purcell SM, Wray NR, et al. (2009) Common polygenic variation contributes to risk of schizo-phrenia and bipolar disorder. Nature 460: 748–752.

Issa G, Wilson C, Terry AV, et al. (2010) An inverse relationship between cortisol and BDNF levels in schizophrenia: data from human post-mortem and animal studies. Neurobiology of Disease 39: 327–333.

Johansson V, Nybom R, Wetterberg L, et al. (2012) Microscopic particles in two fractions of fresh cerebrospinal fluid in twins with schizophre-nia or bipolar disorder and in healthy controls. PLoS One, 7: e45994.

Jonsen A, Bengtsson AA, Sturfelt G, et al. (2004) Analysis of HLA DR, HLA DQ, C4A, FcgammaRIIa, FcgammaRIIIa, MBL, and IL-1Ra allelic variants in Caucasian systemic lupus erythematosus patients suggests an effect of the combined FcgammaRIIa R/R and IL-1Ra 2/2 genotypes on disease susceptibility. Arthritis Research and Therapy 6: R557–R562.

Joseph FG, Lammie GA and Scolding NJ (2007) CNS lupus: a study of 41 patients. Neurology 69: 644–654.

Kahl KG, Bens S, Ziegler K, et al. (2006) Cortisol, the cortisol-dehydroe-piandrosterone ratio, and pro-inflammatory cytokines in patients with current major depressive disorder comorbid with borderline personal-ity disorder. Biological Psychiatry 59: 667–671.

Kaindl AM, Degos V, Peineau S, et al. (2012) Activation of microglial N-methyl-D-aspartate receptors triggers inflammation and neuronal cell death in the developing and mature brain. Annals of Neurology 72: 536–549.

Kapadia M and Sakic B (2011) Autoimmune and inflammatory mecha-nisms of CNS damage. Progress in Neurobiology 95: 301–333.

Kapczinski F, Dias VV, Frey BN, et al. (2009) Brain-derived neurotrophic factor in bipolar disorder: beyond trait and state: comment on “Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders”. Bipolar Disorders 11: 221–222.

Kapur S, Phillips AG and Insel TR. (2012) Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it. Molecular Psychiatry 17: 1174–1179.

Karassa FB, Ioannidis JP, Touloumi G, et al. (2000) Risk factors for cen-tral nervous system involvement in systemic lupus erythematosus. QJM: Monthly Journal of the Association of Physicians 93: 169–174.

Kauer-Sant’Anna M, Kapczinski F, Andreazza AC, et al. (2009) Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. International Journal of Neuropsychopharmacology 12: 447–458.

Kayser MS and Dalmau J (2011) The emerging link between autoimmune disorders and neuropsychiatric disease. Journal of Neuropsychiatry and Clinical Neurosciences 23: 90–97.

Kayser MS, Kohler CG and Dalmau J (2010) Psychiatric manifestations of paraneoplastic disorders. American Journal of Psychiatry 167: 1039–1050.

Kim YK, Jung HG, Myint AM, et al. (2007) Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. Journal of Affective Disorders 104: 91–95.

Konradi C, Sillivan SE and Clay HB (2012) Mitochondria, oligodendro-cytes and inflammation in bipolar disorder: evidence from transcrip-tome studies points to intriguing parallels with multiple sclerosis. Neurobiology of Disease 45: 37–47.

Knight JG, Menkes DB, Highton J, et al. (2007) Rationale for a trial of immunosuppressive therapy in acute schizophrenia. Molecular Psychiatry 12: 424–431.

Krishnadas R and Cavanagh J (2012) Depression: an inflammatory illness? Journal of Neurology, Neurosurgery and Psychiatry 83: 495–502.

Kupka RW, Nolen WA, Post RM, et al. (2002) High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium expo-sure. Biological Psychiatry 51: 305–311.

La Cava A (2009) Natural Tregs and autoimmunity. Frontiers in Bioscience 14: 333.

La Cava A and Matarese G. (2004) The weight of leptin in immunity. Nature Reviews Immunology 4: 371–379.

Lampron A, ElAli A and Rivest S (2013) Innate immunity in the CNS: redefining the relationship between the CNS and its environment. Neuron 78: 214–232.

Langan C and McDonald C. (2009) Neurobiological trait abnormalities in bipolar disorder. Molecular Psychiatry 14: 833–846.

Lin PY (2009) State-dependent decrease in levels of brain-derived neuro-trophic factor in bipolar disorder: a meta-analytic study. Neuroscience Letters 466: 139–143.

Page 15: Immune dysregulation and autoimmunity in bipolar disorder ......clinical application Sanil Rege1,2,3 and Suzanne J Hodgkinson4,5 Abstract Objective: Increasing evidence suggests that

1150 ANZJP Articles

Australian & New Zealand Journal of Psychiatry, 47(12)

Liu CY, Tseng MC and Lin PH (2011a) Encephalopathy associated with autoimmune thyroid disease (Hashimoto’s thyroiditis) presenting as depression: a case report. General Hospital Psychiatry 33:, 641.e647–e649.

Liu W, Tang Y and Feng J (2011b) Cross talk between activation of micro-glia and astrocytes in pathological conditions in the central nervous system. Life Sciences 89: 141–146.

López-Armada MJ, Riveiro-Naveira RR, Vaamonde-García C, et al. (2013) Mitochondrial dysfunction and the inflammatory response. Mitochondrion 13: 106–118.

Losif RE, Ekdahl CT, Ahlenius H, et al. (2006) Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. Journal of Neuroscience 26: 9703–9712.

Luo XG and Chen SD (2012) The changing phenotype of microglia from homeostasis to disease. Translational Neurodegeneration 1: 1–13.

Maat P, Graaff E, Beveren NM, et al. (2012) Psychiatric phenomena as ini-tial manifestation of encephalitis by anti-NMDA receptor antibodies. Acta Neuropsychiatrica doi:10.1111/acn.12013 (Epub ahead of print).

McIntosh AM, Maniega SM, Lymer GKS, et al. (2008) White matter trac-tography in bipolar disorder and schizophrenia. Biological Psychiatry 64: 1088–1092.

McKernan DP, Dennison U, Gaszner G, et al. (2011) Enhanced peripheral toll-like receptor responses in psychosis: further evidence of a pro-inflammatory phenotype. Translational Psychiatry 1: e36.

Maes M, Delange J, Ranjan R, et al. (1997) Acute phase proteins in schiz-ophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Research 66: 1–11.

Maes M, Fišar Z, Medina M, et al. (2012a) New drug targets in depres-sion: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates – Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 20: 127–150.

Maes M, Meltzer HY and Bosmans E (2007) Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatrica Scandinavica 89: 346–351.

Maes M, Mihaylova I, Kubera M, et al. (2011) IgM-mediated autoim-mune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology, Journal of Affective Disorders 135: 414–418.

Maes M, Ringel K, Kubera M, et al. (2012b) Increased autoimmune activity against 5-HT: a key component of depression that is asso-ciated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. Journal of Affective Disorders 136: 386–392.

Mahon K, Burdick KE and Szeszko PR (2010) A role for white mat-ter abnormalities in the pathophysiology of bipolar disorder. Neuroscience and Biobehavioral Reviews 34: 533–554.

Mak A, Ho RCM and Lau CS (2009) Clinical implications of neuropsy-chiatric systemic lupus erythematosus. Advances in Psychiatric Treatment 15: 451–458.

Malek-Ahmadi P (2001) Mood disorders associated with interferon treatment: theoretical and practical considerations. Annals of Pharmacotherapy 35: 489–495.

Manji HK, Moore GJ, Rajkowska G, et al. (2000) Neuroplasticity and cel-lular resilience in mood disorders. Molecular Psychiatry 5: 578–593.

Marshak-Rothstein A (2006) Toll-like receptors in systemic autoimmune disease. Nature Reviews Immunology 6: 823–835.

Meinl E, Krumbholz M and Hohlfeld R (2006) B lineage cells in the inflammatory central nervous system environment: migration, main-tenance, local antibody production, and therapeutic modulation. Annals of Neurology 59: 880–892.

Miller AH, Maletic V and Raison CL (2009) Inflammation and its discon-tents: the role of cytokines in the pathophysiology of major depres-sion. Biological Psychiatry 65: 732–741.

Miller AH, Pariante CM and Pearce BD (1999) Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid

resistance and relevance to depression. Advances in Experimental Medicine and Biology 461: 107–116.

Miller CL, Llenos IC, Dulay JR, et al. (2006) Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cor-tex from individuals with schizophrenia and bipolar disorder. Brain Research 1073: 25–37.

Mocellin R, Walterfang M and Velakoulis D (2007) Hashimotos encepha-lopathy: epidemiology, pathogenesis and management. CNS Drugs 21: 799–811.

Monje ML, Toda H and Palmer TD (2003) Inflammatory blockade restores adult hippocampal neurogenesis. Science 302: 1760–1765.

Monov S and Monova D (2008) Classification criteria for neuropsy-chiatric systemic lupus erythematosus: do they need a discussion? Hippokratia 12: 103–107.

Moscavitch SD, Szyper-Kravitz M and Shoenfeld Y (2009) Autoimmune pathology accounts for common manifestations in a wide range of neuro-psychiatric disorders: the olfactory and immune system inter-relationship. Clinical Immunology 130: 235–243.

Mosmann TR and Sad S (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunology Today 17: 138–146.

Mössner R, Heils A, Stöber G, et al. (1998) Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by inter-leukin-6. Neurochemistry International 33: 251–254.

Munkholm K, Vinberg M and Vedel Kessing L (2013) Cytokines in bipolar disorder: a systematic review and meta-analysis. Journal of Affective Disorders 144: 16–27.

Muscal E and Brey RL (2010) Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurologic Clinics 28, 61–73.

Mussig K, Bartels M, Gallwitz B, et al. (2005) Hashimoto’s encephalopa-thy presenting with bipolar affective disorder. Bipolar Disorders 7: 292–297.

Najjar S, Pearlman DM, Alper K, et al. (2013) Neuroinflammation and psychiatric illness. Journal of Neuroinflammation 10: 43.

Neuwelt CM and Young RG (2009) Managing neuropsychiatric lupus: top 10 clinical pearls. Clinical judgment and experience must pre-vail. Available at: www.musculoskeletalnetwork.com/display/arti-cle/1145622/1396901 (consulted January 2013).

Ng PC, Li K, Wong RP, et al. (2003) Proinflammatory and anti-inflamma-tory cytokine responses in preterm infants with systemic infections. Archives of Disease in Childhood. Fetal and Neonatal Edition 88: F209–213.

Nguyen MD, Julien JP and Rivest S (2002) Innate immunity: the miss-ing link in neuroprotection and neurodegeneration? Nature Reviews Neuroscience 3: 216–227.

O’Brien SM, Scully P, Scott LV, et al. (2006) Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. Journal of Affective Disorders 90: 263–267.

Okamoto H, Kobayashi A and Yamanaka H (2010) Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus ery-thematosus. Journal of Biomedicine and Biotechnology 2010, 268436.

Omdal R, Brokstad K, Waterloo K, et al. (2005) Neuropsychiatric distur-bances in SLE are associated with antibodies against NMDA recep-tors. European Journal of Neurology 12: 392–398.

Ortiz-Dominguez A, Hernandez ME, Berlanga C, et al. (2007) Immune variations in bipolar disorder: phasic differences. Bipolar Disorders 9: 596–602.

O’Shea JJ, Ma A and Lipsky P (2002) Cytokines and autoimmunity. Nature Reviews Immunology 2: 37–45.

Pacheco R, Gallart T, Lluis C, et al. (2007) Role of glutamate on T-cell mediated immunity. Journal of Neuroimmunology 185: 9–19.

Padmos RC, Bekris L, Knijff EM, et al. (2004) A high prevalence of organ-specific autoimmunity in patients with bipolar disorder. Biological Psychiatry. 56: 476–482.

Padmos RC, Hillegers MH, Knijff EM, et al. (2008) A discriminating messenger RNA signature for bipolar disorder formed by an aberrant

Page 16: Immune dysregulation and autoimmunity in bipolar disorder ......clinical application Sanil Rege1,2,3 and Suzanne J Hodgkinson4,5 Abstract Objective: Increasing evidence suggests that

Rege and Hodgkinson 1151

Australian & New Zealand Journal of Psychiatry, 47(12)

expression of inflammatory genes in monocytes. Archives of General Psychiatry 65: 395–407.

Padmos RC, Van Baal GCM, Vonk R, et al. (2009) Genetic and environ-mental influences on pro-inflammatory monocytes in bipolar disor-der: a twin study. Archives of General Psychiatry 66: 957.

Petri M, Naqibuddin M, Carson KA, et al. (2008) Brain magnetic reso-nance imaging in newly diagnosed systemic lupus erythematosus. Journal of Rheumatology 35: 2348–2354.

Plotnikoff NP (2007) Cytokines: stress and immunity. Boca Raton, FL: CRC Press.

Popescu A and Kao AH (2011) Neuropsychiatric systemic lupus erythe-matosus. Current Neuropharmacology 9: 449–457.

Rao JS, Harry GJ, Rapoport SI, et al. (2010) Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipo-lar disorder patients. Molecular Psychiatry 15: 384–392.

Ransohoff RM and Brown MA (2012) Innate immunity in the central nervous system. Journal of Clinical Investigation 122: 1164–1171.

Renault PF, Hoofnagle JH, Park Y, et al. (1987) Psychiatric complications of long-term interferon alfa therapy. Archives of Internal Medicine 147: 1577–1580.

Rohleder N, Wolf JM, Kirschbaum C, et al. (2009) Effects of cortisol on emotional but not on neutral memory are correlated with periph-eral glucocorticoid sensitivity of inflammatory cytokine production. International Journal of Psychophysiology 72: 74–80.

Rosenfeld MR and Dalmau J (2011) Anti-NMDA-receptor encephalitis and other synaptic autoimmune disorders. Current Treatment Options in Neurology 13: 324–332.

Rossi B, Angiari S, Zenaro E, et al. (2011) Vascular inflammation in central nervous system diseases: adhesion receptors controlling leukocyte-endothelial interactions. Journal of Leukocyte Biology 89: 539–556.

Santer DM, Yoshio T, Minota S, et al. (2009) Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. Journal of Immunology 182: 1192–1201.

Schroeter ML, Sacher J, Steiner J, et al. (2013) Serum S100B represents a new biomarker for mood disorders. Current Drug Targets (Epub ahead of print).

Segerstrom SC and Miller GE (2004) Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. Psychological Bulletin 130: 601–630.

Shalev H, Serlin Y and Friedman A (2009) Breaching the blood–brain bar-rier as a gate to psychiatric disorder. Cardiovascular Psychiatry and Neurology 2009, 278531.

Sidhom O, Laadhar L, Zitouni M, et al. (2012) Spectrum of autoantibod-ies in Tunisian psychiatric inpatients. Immunological Investigations 41: 538–549.

Smith TJ (2010) Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacological Reviews 62: 199–236.

Soczynska JK, Kennedy SH, Goldstein BI, et al. (2009) The effect of tumor necrosis factor antagonists on mood and mental health-asso-ciated quality of life: novel hypothesis-driven treatments for bipolar depression? Neurotoxicology 30: 497–521.

Soderlund J, Olsson SK, Samuelsson M, et al. (2011) Elevation of cer-ebrospinal fluid interleukin-1 beta in bipolar disorder. Journal of Psychiatry and Neuroscience 36: 114–118.

Spivak B, Radwan M, Bartur P, et al. (1996) Antinuclear autoantibodies in relation to bipolar affective disorder and lithium therapy. European Psychiatry 11: 50–52.

Squassina A, Costa M, Congiu D, et al. (2013) Insulin-like growth fac-tor 1 (IGF-1) expression is up-regulated in lymphoblastoid cell lines of lithium responsive bipolar disorder patients. Pharmacological Research 73C: 1–7.

Stockinger B and Veldhoen M (2007) Differentiation and function of Th17 T cells. Current Opinion in Immunology 19: 281–286.

Stojanovich L and Marisavljevich D (2008) Stress as a trigger of autoim-mune disease. Autoimmunity Reviews 7: 209–213.

Stout SC and Nemeroff CB (1994) Stress and psychiatric disorders. Seminars in Neuroscience 6: 271–280.

Tedla Y, Shibre T, Ali O, et al. (2011) Serum antibodies to Toxoplasma gondii and Herpesvidae family viruses in individuals with schizo-phrenia and bipolar disorder: a case-control study. Ethiopian Medical Journal 49: 211.

Thomas AJ, Davis S, Ferrier IN, et al. (2004) Elevation of cell adhesion molecule immunoreactivity in the anterior cingulate cortex in bipolar disorder. Biological Psychiatry 55: 652–655.

Tyring S, Gottlieb A, Papp K, et al. (2006) Etanercept and clinical out-comes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367: 29–35.

Valles SL, Blanco AM, Pascual M, et al. (2004) Chronic ethanol treatment enhances inflammatory mediators and cell death in the brain and in astrocytes. Brain Pathology 14: 365–371.

Viviani B, Bartesaghi S, Gardoni F, et al. (2003) Interleukin-1β enhances NMDA receptor-mediated intracellular calcium increase through activa-tion of the Src family of kinases. Journal of Neuroscience 23: 8692–8700.

Vonk R, van der Schot AC, Kahn RS, et al. (2007) Is autoimmune thyroidi-tis part of the genetic vulnerability (or an endophenotype) for bipolar disorder? Biological Psychiatry 62: 135–140.

Wadee AA, Kuschke RH, Wood LA, et al. (2002) Serological obser-vations in patients suffering from acute manic episodes. Human Psychopharmacology: Clinical and Experimental 17: 175–179.

Waite JC and Skokos D (2012) Th17 response and inflammatory autoim-mune diseases. International Journal of Inflammation 2012, 819467.

Wallace DJ and Hahn BH (2006) Dubois’ lupus erythematosus. Philadelphia, PA: Lippincott Williams and Wilkins.

Webster MJ, O’Grady J, Kleinman JE, et al. (2005) Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depres-sion, bipolar disorder and schizophrenia. Neuroscience 133: 453–61.

Wright MT (2010) Neuropsychiatric illness in systemic lupus erythema-tosus: insights from a patient with erotomania and Geschwind’s syn-drome. American Journal of Psychiatry 167: 502–507.

Yeh HM and Hu SY (2007) Mania as an initial feature of systemic lupus erythematosus: a case report. Journal of Internal Medicine of Taiwan 18: 283–286.

Yu HH, Lee JH, Wang LC, et al. (2006) Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study. Lupus 15: 651–657.

Zanetti MV, Jackowski MP, Versace A, et al. (2009) State-dependent micro-structural white matter changes in bipolar I depression. European Archives of Psychiatry and Clinical Neuroscience 259: 316–328.

Zhang B, Angelidou A, Alysandratos KD, et al. (2010) Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children. J Neuroinflammation 7: 80.

Zhu CB, Carneiro AM, Dostmann WR, et al. (2005) p38 MAPK activa-tion elevates serotonin transport activity via a trafficking-independ-ent, protein phosphatase 2A-dependent process. Journal of Biological Chemistry 280: 15649–15658.

Zhu J and Paul WE (2008) CD4 T cells: fates, functions, and faults. Blood 112: 1557–1569.

Zotova E, Nicoll JA, Kalaria R, et al. (2010) Inflammation in Alzheimer’s disease: relevance to pathogenesis and therapy. Alzheimers Research and Therapy 2: 1.

Zou J, Wang YX, Dou FF, et al. (2010) Glutamine synthetase down-regu-lation reduces astrocyte protection against glutamate excitotoxicity to neurons. Neurochemistry International 56: 577–584.